Driest skin she ever had; Lips were chapped; Nose is dry; Eyelids are dry; Low fever; Arm was sore; This spontaneous case was reported by an other health care professional and describes the occurrence of PAIN IN EXTREMITY (Arm was sore), DRY SKIN (Driest skin she ever had), CHAPPED LIPS (Lips were chapped), NASAL DRYNESS (Nose is dry) and EYELID SKIN DRYNESS (Eyelids are dry) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unk) for COVID-19 vaccination.     The patient's past medical history included No adverse event (no medical history reported).    On 23-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Dec-2020, the patient experienced PAIN IN EXTREMITY (Arm was sore). On 25-Dec-2020, the patient experienced DRY SKIN (Driest skin she ever had), CHAPPED LIPS (Lips were chapped), NASAL DRYNESS (Nose is dry) and EYELID SKIN DRYNESS (Eyelids are dry). The patient was treated with BACITRACIN ZINC, POLYMYXIN B SULFATE (AQUAPHOR ANTIBIOTIC) at an unspecified dose and frequency and DIMETICONE (CHAPSTICK) at an unspecified dose and frequency. On 24-Dec-2020, PAIN IN EXTREMITY (Arm was sore) had resolved. At the time of the report, DRY SKIN (Driest skin she ever had), CHAPPED LIPS (Lips were chapped), NASAL DRYNESS (Nose is dry) and EYELID SKIN DRYNESS (Eyelids are dry) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 23-Dec-2020, Body temperature: 100 (Inconclusive) 100 degrees.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Company comment: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.  This case concerns a 33-year-old female patient, who experienced a non- serious unexpected event of pain in extremity, dry skin, eyelid skin dryness, nasal dryness, chapped lips, and non-serious expected event of pyrexia. The event of pyrexia and pain in extremity occurred 1 day (same day) after first dose of mRNA-1273, lot # unknown. The event of dry skin, eyelid skin dryness, nasal dryness, chapped lips   occurred 2 days after first dose of mRNA-1273, lot # unknown. Treatment included Aquaphor and humidifier. Based on the current available information and temporal association between the use of the product and onset of the events a causal relationship cannot be excluded.   Most recent FOLLOW-UP information incorporated above includes: On 31-Jan-2021: Follow up information was received on 31-Jan-2021: contains no new information; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.  This case concerns a 33-year-old female patient, who experienced a non- serious unexpected event of pain in extremity, dry skin, eyelid skin dryness, nasal dryness, chapped lips, and non-serious expected event of pyrexia. The event of pyrexia and pain in extremity occurred 1 day (same day) after first dose of mRNA-1273, lot # unknown. The event of dry skin, eyelid skin dryness, nasal dryness, chapped lips   occurred 2 days after first dose of mRNA-1273, lot # unknown. Treatment included Aquaphor and humidifier. Based on the current available information and temporal association between the use of the product and onset of the events a causal relationship cannot be excluded.